Qube Research & Technologies (QRT)
GALT icon

Qube Research & Technologies (QRT)’s Galectin Therapeutics GALT Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-126,439
Closed -$353K – 3694
2026
Q1 		$353K Buy
126,439
+51,796
+69% +$158K ﹤0.01% 2835
2025
Q4 		$311K Buy
74,643
+13,776
+23% +$72.5K ﹤0.01% 2941
2025
Q3 		$258K Buy
60,867
+45,297
+291% +$170K ﹤0.01% 2886
2025
Q2 		$32.9K Buy
15,570
+391
+3% +$585 ﹤0.01% 3207
2025
Q1 		$18.5K Buy
15,179
+3,049
+25% +$4.28K ﹤0.01% 3226
2024
Q4 		$15.6K Buy
+12,130
New +$29.1K ﹤0.01% 3202
2024
Q2 		– Sell
-69,045
Closed -$165K – 4127
2024
Q1 		$165K Sell
69,045
-6,367
-8% -$12K ﹤0.01% 3115
2023
Q4 		$125K Buy
75,412
+71,790
+1,982% +$139K ﹤0.01% 3015
2023
Q3 		$6.95K Buy
+3,622
New +$5.96K ﹤0.01% 3390

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Qube Research & Technologies (QRT)'s GALT Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 126,439 shares — an estimated $353K sold.

Qube Research & Technologies (QRT) first reported a position in GALT in Q3 2023 and held it in 9 quarters. The position peaked at $353K in Q1 2026. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 126,439 Galectin Therapeutics shares in Q2 2026, an estimated $353K.
  • Qube Research & Technologies (QRT) first reported a position in Galectin Therapeutics in Q3 2023 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s Galectin Therapeutics position peaked at $353K in Q1 2026.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.